New drug aims to boost CAR-T results for tough lymphoma cases
NCT ID NCT05464719
Summary
This study is testing whether a drug called loncastuximab tesirine can help control large B-cell lymphoma in patients whose cancer has come back or didn't fully respond to previous treatments. The research focuses on people who showed a partial response after receiving CAR T-cell therapy, aiming to see if this additional treatment can turn that partial response into a complete remission. About 30 participants will receive the study drug to evaluate both its effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.